welcomes you to the new, improved website!This study compared the development of de novo aortic insufficiency (AI), the a common adverse event after continuous-flow left ventricular assist device (LVAD) placement, between HeartMate 3 (Abbott) and HeartMate II LVAD recipients. Researchers ultimately concluded there is no significant difference in severity of AI between HeartMate II and HeartMate 3 patients.
You are here:
Development of De Novo Aortic Insufficiency in Patients With HeartMate 3
Source: Annals of Thoracic Surgery
Source URL: https://doi.org/10.1016/j.athoracsur.2021.08.074
Keywords:
Author(s): Alyyah Malick, BA, Yuming Ning, PhD, Paul A. Kurlansky, MD, Andrew Melehy, MD, Melana Yuzefpolskaya, MD, Paolo C. Colombo, MD, Gabriel Sayer, MD, Nir Uriel, MD, MSc, Yoshifumi Naka, MD, PhD, and Koji Takeda, MD, PhD
